NKP608 是 4-氨基哌啶的非肽类衍生物,是一种高选择性、口服有效的神经激肽-1 (NK1) 受体拮抗剂(IC50 为 2.6 nM),在体外和体内均具有活性,对 NK2 和 NK3 受体的亲和力极低,通过阻断 NK1 受体调节细胞增殖和凋亡 (apoptosis)、影响神经递质功能和胃黏膜修复机制,并通过抑制 Wnt/β-catenin 通路发挥抗肿瘤作用,可应用于咳嗽、焦虑症、抑郁症、胃黏膜损伤和结直肠癌等多种疾病的研究。
产品编号: MS-M25614 纯度: 99.88% CAS No.: 177707-12-9 分子式: C31H24ClF6N3O2 分子量: 619.98
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

NKP608 是 4-氨基哌啶的非肽类衍生物,是一种高选择性、口服有效的神经激肽-1 (NK1) 受体拮抗剂(IC50 为 2.6 nM),在体外和体内均具有活性,对 NK2 和 NK3 受体的亲和力极低,通过阻断 NK1 受体调节细胞增殖和凋亡 (apoptosis)、影响神经递质功能和胃黏膜修复机制,并通过抑制 Wnt/β-catenin 通路发挥抗肿瘤作用,可应用于咳嗽、焦虑症、抑郁症、胃黏膜损伤和结直肠癌等多种疾病的研究。

生物实验数据

生物活性 NKP608, a non-peptide derivative of 4-aminopiperidine, is a highly selective and orally active neurokinin-1 (NK1) receptor antagonist with an IC50 of 2.6 nM that is active both in vitro and in vivo and exhibits extremely low affinity for NK2 and NK3 receptors; by blocking the NK1 receptor, it modulates cell proliferation and apoptosis (apoptosis), affects neurotransmitter function and gastric mucosal repair mechanisms, and exerts antitumor effects through inhibition of the Wnt/β-catenin pathway, making it applicable to research on various diseases including cough, anxiety, depression, gastric mucosal injury, and colorectal cancer.
IC50 & Target HSP:13 nM (gerbil midbrain), HSP:27 nM (rat striatum), IP1:2.6 nM, HSP:2.6 nM (bovine retina)
体外研究
(In Vitro)

NKP608 与人重组 NK1 受体结合,pKi 为 8.96,对人重组 NK2 (pKi: 6.1) 和 NK3 (pKi: 6.25) 受体亲和力较低。
NKP608 结合牛视网膜 (IC50: 2.6 nM)、沙鼠中脑 (IC50: 13 nM) 和大鼠纹状体 (IC50: 27 nM) 中的 NK1 受体,对牛膀胱中 NK2 受体 (IC50: 2100 nM) 和沙鼠皮层中 NK3 受体 (IC50: 1500 nM) 亲和力低。
NKP608 (1 μM; 1 小时) 使人克隆 NK1 受体 CHO 细胞中肌醇磷酸合成 EC50 移位 20 倍,并抑制大鼠 NK1 受体 CHO 细胞中 P 物质诱导的酸化率增加。
NKP608 (0.001-100 μM; 72 h) 以浓度依赖的方式抑制人结直肠癌HCT116细胞的增殖。
NKP608 (10 μM; 24 h) 抑制人结直肠癌 HCT116 细胞的迁移和侵袭。NKP608 诱导人结直肠癌 HCT116 细胞凋亡,下调 Bcl-2 的表达,上调 Bax 和活性 Caspase-3 的表达。NKP608 降低人结直肠癌 HCT116 细胞中 Wnt-3a、β-catenin、Cyclin D1 和 VEGF 的表达,并诱导 E-Cadherin 的表达。

Cell Viability Assay

Cell Line: HCT116 cells (human colorectal cancer)
Concentration: 0.001 μM, 0.01 μM, 0.1 μM, 1 μM, 10 μM, 100 μM
Incubation Time: 72 h
Result: Inhibits proliferation of HCT116 cells in a concentration-dependent manner.

Cell Proliferation Assay

Cell Line: HCT116 cells (human colorectal cancer)
Concentration: 10 μM
Incubation Time: 24 h, 48 h, 72 h
Result: Significantly inhibits migration of HCT116 cells.

Cell Invasion Assay

Cell Line: HCT116 cells (human colorectal cancer)
Concentration: 10 μM
Incubation Time: 24 h
Result: Significantly inhibits invasion of HCT116 cells.

Apoptosis Analysis

Cell Line: HCT116 cells (human colorectal cancer)
Concentration: 10 μM
Incubation Time: 24 h
Result: Induces apoptosis of HCT116 cells.

Western Blot Analysis

Cell Line: HCT116 cells (human colorectal cancer)
Concentration: 10 μM
Incubation Time: 24 h
Result: Downregulates expressions of Bcl-2, Wnt-3a, β-catenin, Cyclin D1 and VEGF; upregulates expressions of Bax, Active-Caspase-3 and E-Cadherin.
体内研究
(In Vivo)

NKP608 (0.03, 0.3, 1 mg/kg; p.o.; once; 2 h prior to challenge) 可显著降低 Dunkin Hartley 豚鼠的柠檬酸诱导咳嗽。
NKP608 (0.003, 0.03, 0.3 mg/kg; p.o.; once; 90 min prior to test) 在雄性自发性高血压大鼠 (SHR) 的旷场实验中表现出抗焦虑样作用,在雄性 Lewis 大鼠的高架十字迷宫 (EPM) 实验中表现出部分抗焦虑样作用。
NKP608 (0.2 mg/kg; i.v.; once; immediately prior to agonist challenge) 可强效抑制蒙古沙鼠的 GR73632 (MS-G81453) 诱导后足敲击。
NKP608 (0.01, 0.1, 0.3 mg/kg; p.o.; once; 2 h prior to test) 可增加蒙古沙鼠的社交探索时间,显示出显著的抗焦虑作用。
NKP608 (0.03-3 mg/kg; p.o.; once; 2, 5 or 24 h prior to agonist administration) 可剂量依赖性抑制蒙古沙鼠的 SPOMe 诱导后足敲击,ID50 值分别为 0.23 mg/kg (2 h)、0.15 mg/kg (5 h) 和 0.38 mg/kg (24 h)。
NKP608 (0.01-1 mg/kg; p.o.; once; 90 min prior to test) 可在高光照陌生环境中特异性增加 Sprague-Dawley 大鼠的主动社交互动时间。
NKP608 (0.03-3 mg/kg; p.o.; once; 90 min prior to test) 可增加 Sprague-Dawley 大鼠中入侵者大鼠对居留者大鼠的社交探索时间。
NKP608 (1 mg/kg; i.g.; once daily; for 8 consecutive days) 可延迟野生型和 COX-2-/- 小鼠的胃冷冻溃疡愈合,并减少溃疡边缘 Ki-67 阳性上皮细胞数量。

Animal Model: Dunkin Hartley guinea pigs (250-500 g; no gender specified) were exposed to nebulized citric acid (0.6 M) for 10 min to induce cough and airway obstruction.
Dosage: NKP608: 0.03, 0.3, 1 mg/kg; single drug administration
Administration: Oral (p.o.) administration; once; 2 h prior to citric acid challenge
Result: Significantly reduces the number of citric acid-induced coughs by 77% (0.03 mg/kg), 74% (0.3 mg/kg) and 79% (1 mg/kg), respectively; does not significantly reduce citric acid-induced increase in enhanced pause (Penh).
Animal Model: Male spontaneously hypertensive rats (SHR) and male Lewis rats (9 weeks old; body weight: SHR males 232 g, LEW males 234 g) were subjected to elevated plus-maze (EPM) and open field (OF) tests to evaluate anxiety-related behaviors.
Dosage: 0.003, 0.03, 0.3 mg/kg
Administration: Oral (p.o.) administration; once; 90 min prior to tests
Result: Exerts anxiolytic-like effects in male SHR rats in the OF test.
Shows partial anxiolytic-like effects in male Lewis rats in the EPM test.
Has no significant anxiolytic effects in female SHR or Lewis rats in either test.
Animal Model: Mongolian gerbils (40-60 g; no gender specified) were intracerebroventricularly (i.c.v.) injected with GR73632 (3 pmol/5 μL) to induce foot drumming behavior.
Dosage: 0.2 mg/kg
Administration: Intravenous (i.v.) injection; once; immediately prior to GR73632 administration
Result: Potently inhibits GR73632-induced foot drumming in Mongolian gerbils.
Animal Model: Mongolian gerbils (70-85 g; male) were subjected to the social investigation test to evaluate anxiety-related behaviors.
Dosage: 0.01, 0.1, 0.3 mg/kg
Administration: Oral (p.o.) administration; once; 2 h prior to test
Result: Increases the time of social investigation towards an untreated, unfamiliar partner.
Animal Model: Mongolian gerbils (70-80 g; male) were intracerebroventricularly (i.c.v.) injected with SPOMe (1 μg/5 μL) to induce hind foot thumping behavior.
Dosage: 0.1, 0.3 mg/kg
Administration: Oral (p.o.) administration; once daily; for 7 consecutive days
Result: Attenuates SPOMe-induced hind foot thumping when tested 2 h or 24 h after the last administration.
Animal Model: Sprague-Dawley rats (180-200 g; male) were subjected to the social interaction test in a highly illuminated unfamiliar arena (65×65×45 cm).
Dosage: 0.001 mg/kg, 0.01 mg/kg, 0.1 mg/kg, 1 mg/kg
Administration: Oral (p.o.) administration; once; 90 min prior to test
Result: Specifically increases active social interaction time between unfamiliar rats and does not affect general activity parameters.
Animal Model: Wild-type and COX-2-/- mice (20-24 g; female; 7-8 weeks old) were subjected to laparotomy to induce gastric cryoulcers via serosal application of a CO2-cooled cryoprobe (15 s).
Dosage: 1 mg/kg
Administration: Intragastric (i.g.) administration; once daily; for 8 consecutive days
Result: Delays gastric cryoulcer healing in both wild-type and COX-2⁻/⁻ mice and decreases the number of Ki-67-positive epithel.
Animal Model: Sprague-Dawley rats (residents: 350-400 g, male; intruders: 100-120 g, male, Lister Hooded strain) were subjected to the social exploration test.
Dosage: 0.03 mg/kg, 0.3 mg/kg, 3 mg/kg
Administration: Oral (p.o.) administration; once; 90 min prior to test (administered to intruder rats only)
Result: Increases the time of active social exploration of intruder rats towards resident rats.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 619.98
分子式 C31H24ClF6N3O2
CAS No. 177707-12-9

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (5.32 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (161.30 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.6130 mL8.0648 mL16.1296 mL40.3239 mL
5 mM0.3226 mL1.6130 mL3.2259 mL8.0648 mL
10 mM0.1613 mL0.8065 mL1.6130 mL4.0324 mL
15 mM0.1075 mL0.5377 mL1.0753 mL2.6883 mL
20 mM0.0806 mL0.4032 mL0.8065 mL2.0162 mL
25 mM0.0645 mL0.3226 mL0.6452 mL1.6130 mL
30 mM0.0538 mL0.2688 mL0.5377 mL1.3441 mL
40 mM0.0403 mL0.2016 mL0.4032 mL1.0081 mL
50 mM0.0323 mL0.1613 mL0.3226 mL0.8065 mL
60 mM0.0269 mL0.1344 mL0.2688 mL0.6721 mL
80 mM0.0202 mL0.1008 mL0.2016 mL0.5040 mL
100 mM0.0161 mL0.0806 mL0.1613 mL0.4032 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础